12,693 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Fi3 FINANCIAL ADVISORS LLC

Fi3 FINANCIAL ADVISORS LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,693 shares of the biopharmaceutical company's stock, valued at approximately $337,000.

A number of other institutional investors and hedge funds also recently modified their holdings of PFE. Charles Schwab Investment Management Inc. raised its position in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Pfizer in the 4th quarter worth approximately $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Pfizer by 79.5% during the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after purchasing an additional 4,938,209 shares during the period. Finally, Van ECK Associates Corp increased its position in Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after buying an additional 4,726,549 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Price Performance

NYSE:PFE traded down $0.58 during trading hours on Tuesday, hitting $25.56. 47,484,282 shares of the company's stock traded hands, compared to its average volume of 36,645,983. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The business's fifty day simple moving average is $26.15 and its two-hundred day simple moving average is $27.02. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $144.96 billion, a P/E ratio of 18.13, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter last year, the company posted $0.10 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PFE. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Bank of America reissued a "neutral" rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.